LUNAC Therapeutics Secures Over €3M to Develop Novel Anticoagulants
LUNAC Therapeutics has spun out of the University of Leeds with €3.09M of funding from the university and the VC firm Epidarex Capital for the development of anticoagulants with a lower risk for bleeding than those currently available. The new anticoagulants
Dragonfly Therapeutics Initiates Phase 1/2 Study of DF1001 in Patients with Advanced Solid Tumors
Dragonfly Therapeutics, a biotechnology company developing novel immunotherapies that harness the innate immune system to treat disease, announced that the first patient was dosed in a Phase 1/2 study of DF1001 at The University of Texas MD Anderson Cancer Center
FUJIFILM Diosynth Biotechnologies Announces $55 Million USD Investment To Expand Gene Therapy Development Capabilities
FUJIFILM Diosynth Biotechnologies will be expanding its gene therapy process and analytical development capabilities with the addition of new dedicated laboratorios. FUJIFILM Diosynth Biotechnologies (FDB), a leading global biologics Contract Development and Manufacturing Organization (CDMO) has announced the expansion of
Merck Licenses CRISPR Gene-Editing Technology to Evotec
Merck, a leading science and technology company, announced that it has signed a license agreement providing Evotec SE access to Merck's foundational CRISPR intellectual property. Evotec, an international biotechnology company headquartered in Hamburg, Germany, will use Merck's CRISPR genome-editing technology
Hallura, an aesthetic medical company developing a new generation of Hyaluronic Acid Dermal Fillers, Closes Its $7M Financing Round
Hallura Ltd., an Israeli based aesthetic medical company developing a new generation of Hyaluronic Acid (HA) Dermal Fillers, closes its A round of $7M. The financing round was led by a group of US, Europe and Israel-based private investors; most
FDA authorized Vela Diagnostics’ Sentosa SQ HIV Genotyping Assay
The Food and Drug Administration has given the go-ahead to what it calls the first next-generation sequencing test for detecting mutations that enable the most common strain of HIV to become immune to drugs. The FDA said that it had authorized
Enterome Enters Collaboration With Major Cancer Center Focused on New Microbiome-derived Immunotherapies
ENTEROME, a clinical-stage biopharmaceutical company leveraging its unique knowledge of the key functional and molecular interactions between the gut microbiome and the human body to develop targeted therapeutics, has entered into a research collaboration with Memorial Sloan Kettering Cancer Center
Shape Therapeutics raises $35.5M Series A round to develop RNA-based gene editing technology
A company developing a means to edit RNA has raised more than $30 million in a venture capital funding round. Seattle-based Shape Therapeutics, or ShapeTx, said that it had raised a $35.5 million Series A financing, led by New Enterprise Associates
Digital pathology startup PathAI closes $75M Series B round with investments from BMS & Merck
Two of the largest drugmakers in the country are investing in a startup applying artificial intelligence in pathology. Boston-based PathAI said that it had closed its $75 million Series B financing round with funding from New York-based Bristol-Myers Squibb and
Coherus as Marketing and Distribution Partner for Bioeq and Its Biosimilar to Lucentis (ranibizumab) in the US
Bioeq announced that it signed a license and development agreement with Coherus BioSciences, under which Coherus will exclusively market and distribute Bioeq's biosimilar candidate to Lucentis (ranibizumab) in the United States. Coherus BioSciences is a leading biosimilar company that develops and